- Home
- TLSA vs WHF Comparison
TLSA vs WHF Comparison
Compare TLSA & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSA | WHF |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 152.5M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TLSA | WHF |
|---|---|---|
| Price | $1.18 | $7.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.02 | $7.83 |
| AVG Volume (30 Days) | ★ 582.2K | 101.0K |
| Earning Date | 05-01-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 14.87% |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.38 |
| P/E Ratio | ★ N/A | $15.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $6.07 |
| 52 Week High | $2.20 | $7.84 |
Technical Indicators
Market Signals| Indicator | TLSA | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 48.97 |
| Support Level | $1.14 | $6.85 |
| Resistance Level | $1.20 | $7.22 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 76.81 | 46.14 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.